Dr Mohit Bhandari (For the Motion)

1. There should be no battle between bariatric surgeons and Endocrinologists.
2. We should together battle the chronic recalcitrant disease-morbid obesity and type 2 diabetes.
3. Normal BMI and overweight diabetics should primarily be treated by medical therapies but at the same time we need to conduct randomized control trials on normal BMI and overweight type 2 diabetics with good insulin reserve to compare outcomes between surgical and medical therapy.
4. Refractory cases with uncontrolled type 2 diabetes may gain from metabolic surgery which is suggested by mid-term data.
5. Nip them in the bud should be the policy.

Dr Sachin Chittawar (Against the Motion)

1. Long-term (beyond 10 years) efficacy and safety data are lacking.
2. Factors predicting T2DM remission and relapse after surgery are still incompletely characterized.
3. There is still insufficient evidence to clearly define cut-off values for T2DM duration or laboratory markers that might be able to quantitatively predict T2DM remission over time.
4. Available studies include a modest number of patients with a BMI between 30 and 35 kg/m2.
5. There are limited comparative (head-to-head) data for distinct surgical interventions in terms of cardiometabolic outcomes.
6. The relationship between the duration of T2DM remission and the incidence of micro- and macrovascular complications remains unclear.